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Background:  In  the ﬁrst  ﬁve  I-MOVE  (Inﬂuenza  Monitoring  Vaccine  Effectiveness  in  Europe)  inﬂuenza
seasons  vaccine  effectiveness  (VE)  results  were  relatively  homogenous  among  participating  study  sites.
In 2013–2014,  we  undertook  a multicentre  case-control  study  based  on  sentinel  practitioner  surveil-
lance  networks  in  six  European  Union  (EU)  countries  to  measure  2013–2014  inﬂuenza  VE  against
medically-attended  inﬂuenza-like  illness  (ILI) laboratory-conﬁrmed  as  inﬂuenza.  Inﬂuenza  A(H3N2)  and
A(H1N1)pdm09  viruses  co-circulated  during  the  season.
Methods:  Practitioners  systematically  selected  ILI  patients  to swab  within  eight  days  of  symptom  onset.
We  compared  cases  (ILI positive  to inﬂuenza  A(H3N2)  or A(H1N1)pdm09)  to inﬂuenza  negative
patients.  We  calculated  VE for  the  two inﬂuenza  A  subtypes  and  adjusted  for  potential  confounders.
We  calculated  heterogeneity  between  sites  using  the  I2 index  and  Cochrane’s  Q  test.  If the I2 was  <50%,
we  estimated  pooled  VE  as (1 minus  the OR)  ×  100  using  a one-stage  model  with  study  site  as  a  ﬁxed
effect.  If the  I2 was  >49%  we  used  a  two-stage  random  effects  model.
Results:  We  included  in the  A(H1N1)pdm09  analysis  531  cases  and 1712  controls  and  in  the A(H3N2)
analysis  623  cases  and  1920  controls.  For  A(H1N1)pdm09,  the  Q test  (p  =  0.695)  and the  I2 index  (0%)
suggested  no heterogeneity  of adjusted  VE  between  study  sites.  Using  a one-stage  model,  the  overall
pooled  adjusted  VE against  inﬂuenza  A(H1N1)pdm2009  was 47.5%  (95%  CI: 16.4–67.0).
For  A(H3N2),  the  I2 was  51.5%  (p = 0.067).  Using  a  two-stage  model  for the  pooled  analysis,  the  adjusted
VE  against  A(H3N2)  was  29.7  (95%  CI: −34.4–63.2).
Conclusions:  The  results  suggest  a  moderate  2013–2014  inﬂuenza  VE against  A(H1N1)pdm09  and  a  low
VE  against  A(H3N2).  The  A(H3N2)  estimates  were  heterogeneous  among  study  sites. Larger sample  sizes
by  study  site  are  needed  to  prevent  statistical  heterogeneity,  decrease  variability  and  allow  for  two-stage
pooled  VE  for  all  subgroup  analyses.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
. Introduction
In February 2013, the World Health Organization
WHO) recommendations for the 2013–2014 trivalent
nﬂuenza vaccine for the Northern Hemisphere were to
nclude an A/California/7/2009(H1N1)pdm09-like virus, an
(H3N2) virus antigenically like the cell-propagated pro-
otype virus A/Victoria/361/2011 (A/Texas/50/2012) and a
/Massachusetts/2/2011-like virus. The A/Victoria/361/2011-
ike vaccine viruses used as A(H3N2) component in the 2012–2013
accine had antigenic changes resulting from adaptation to
ropagation in eggs. Consequently, WHO  recommended to use
s A(H3N2) 2013–2014 component A/Texas/50/2012 [1]. The
(H1N1)pdm09 vaccine component was the same recommended
ince 2009.
In Europe, up to 2014, the European Medicines Agency (EMA)
equired vaccine manufacturers to conduct small clinical trials with
he newly recommended seasonal inﬂuenza vaccines.
On 23rd January 2014, the EMA  notiﬁed inﬂuenza vaccine
roducers that from the 2015–2016 season those trials were
o longer requested. To strengthen post-marketing monitoring
f the performance of inﬂuenza vaccines, vaccine manufac-
urers would be required to provide product-speciﬁc vaccine
ffectiveness results and enhance vaccine safety surveillance
2].
Since 2008–2009, the I-MOVE (Inﬂuenza Monitoring Vac-
ine Effectiveness in Europe) multicentre case control study
MCCS) provides vaccine effectiveness (VE) estimates by inﬂuenza
ype/subtype, age-group, target population and, since 2012–2013
y vaccine type [3–7]. If resources for larger sample size were
vailable, I-MOVE MCCS, could routinely measure inﬂuenza VE by
roduct providing results scientiﬁcally independent from vaccine
anufacturers.
The 2013–2014 inﬂuenza season in Europe was mild with co-
irculation of A(H1N1)pdm09 and A(H3N2) viruses [8].
In this 6th season of I-MOVE, we aimed to provide 2013–2014
2. Methods
The six study sites participating in the 2013–2014 multicentre
case-control study were in Germany, Hungary, Ireland, Portugal,
Romania and Spain.
Participating practitioners started to interview ILI patients and
carry out naso-pharyngeal swabbing for the study from 15 days
after the beginning of the 2013–2014 country-speciﬁc seasonal
inﬂuenza vaccination campaigns. Practitioners selected all older
persons (60 or 65 years old and older) and a systematic sample
of patients from other age groups consulting with ILI. In Hungary,
only patients aged over 18 years were eligible. In Germany in case
of no patients consulting for ILI in the week, practitioners sampled
those consulting for Acute Respiratory Infection (ARI).
Practitioners collected information on: date of ILI symptom
onset and date of swabbing; 2013–2014 seasonal inﬂuenza vac-
cination status, date and brand, 2012–2013 seasonal inﬂuenza
vaccination status; ILI signs and symptoms, sex, presence of a
chronic condition (including obesity, except Germany), number of
hospitalisations for chronic conditions in the previous 12 months
and pregnancy. Five study sites collected information on the num-
ber of practitioner visits in the past 12 months and smoking status
(not collected in Germany) and, ﬁve on receipt of antivirals (not
collected in Spain). Three study sites included a speciﬁc question
to identify individuals in the target group for inﬂuenza vaccina-
tion, and three used variables such as age, chronic conditions,
pregnancy and professional or care giver status to enable their
identiﬁcation.
We included patients in the study if they met  the European Com-
mission ILI case deﬁnition (sudden onset of symptoms and at least
one of the following four systemic symptoms: fever or feverish-
ness, malaise, headache, myalgia; and at least one of the following
three respiratory symptoms: cough, sore throat, shortness of
breath), if they were swabbed within seven days of symptom onset
, and did not receive antivirals prior to swabbing.
Swabs were tested for inﬂuenza using real time polymerase
easonal laboratory conﬁrmed inﬂuenza VE against medically-
ttended inﬂuenza like illness (ILI), by inﬂuenza A subtype,
ge-group and vaccine type.chain reaction (PCR) at the respective country’s National Inﬂuenza
Reference Laboratory. In Spain, tests were also conducted in
other laboratories participating in the National Inﬂuenza Sentinel
accine
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urveillance System. The corresponding National Inﬂuenza Centre
enetically characterised a sub-set of positive specimens or isolated
iruses by sequencing the HA1 coding portion of the haemagglu-
inin gene. The Spanish and Portuguese National Inﬂuenza Centre
nalysed all study sequences provided by the laboratories of all
tudy sites and compared the sequences to the reassortant viruses
sed in most vaccine brands: for A(H3N2) to the reassortant virus
-223A (GISAID number EPI407126), and A(H1N1)pdm09 to the
eassortant virus X-179A (GISAID number EPI257201).
We reported amino acid changes if they were present in >5%
f the viruses sequenced. We  used Neighbour-Joining method and
imura 2-parameter nucleotide substitution model for phyloge-
etic analysis. To ensure the comparability of the hemagglutination
nhibition assay (HI) between countries, we used the antigenic
haracterisation results reported by the WHO  Collaborating Cen-
re MRC  National Institute for Medical Research (Mill Hill, London)
8].
Inﬂuenza A(H3N2) and A(H1N1)pdm09 cases were patients
ith the virus subtype identiﬁed and controls were patients testing
egative for any inﬂuenza virus.
For each study site and for each inﬂuenza type/subtype, we
eﬁned the start of the study period as the week of onset of the
rst inﬂuenza type/subtype case recruited. The end of the study
eriod was the week of onset of the last inﬂuenza type/subtype
ase after the peak, after which there were at least two  consecutive
eeks with no further inﬂuenza positive cases of this type/subtype.
We deﬁned a patient as vaccinated if he/she had received at
east one dose of 2013–2014 seasonal inﬂuenza vaccine at least 15
ays before ILI symptom onset. We  considered all other patients
nvaccinated.
For each study site, we computed the odds ratio (OR) of being
accinated in cases versus controls. We  conducted a complete cases
nalysis excluding patients with missing values for any of the vari-
bles We  used the Cochran’s Q-test and the I2 index to test the
eterogeneity between study sites [9]. In study sites with sample
izes large enough we used adjusted ORs and their standard errors,
therwise we used the crude ORs. If the I2 was <50%, we  estimated
he pooled type/subtype inﬂuenza vaccine effectiveness (VE) as (1
inus the OR) × 100 using a one-stage model with study site as a
xed effect. If the I2 was >49% we used a two-stage model using a
andom effects.
For the 1-stage ﬁxed effect models, we used a logistic regression
odel to calculate VE including potential confounding factors: age
modelled as a restricted cubic spline with 4 knots), sex, presence
f at least one chronic condition (including pregnancy and obesity
here available) and week of symptom onset. For country-speciﬁc
stimates used in the two-stage models, the adjustment variables
epended on sample size and included one or more of the follow-
ng potential confounding factors: age (modelled as restricted cubic
pline with 4 knots, or as a binary or categorical variable), sex, pres-
nce of at least one chronic condition (including pregnancy and
besity where available) and time of onset (week or month of onset
r date of onset modelled as a restricted cubic spline with 4 knots).
We stratiﬁed VE into three age groups (0–14, 15–59 and 60 years
nd above) and into three types of vaccines (adjuvanted, split virion,
ubunit).
We conducted three sensitivity analyses (1) restricting the study
o patients swabbed less than 4 days after symptom onset, (2)
estricting to the target population (3) excluding patients vacci-
ated <15 days after symptom onset.. Results
The inﬂuenza season in the countries of the six study sites
tarted and peaked at different times, as deﬁned by national 33 (2015) 2813–2822 2815
thresholds (Table 1). The season started earliest in Portugal, Roma-
nia and Spain (week 1, 2014) and latest in Germany, (week 8,
2014). The peak of the inﬂuenza season varied from week 4, 2014
in Portugal and Spain to week 11, 2014 in Romania.
Among the 4292 ILI/ARI patients recruited, 3196 ILI patients
met  the eligibility criteria: 1986 testing negative for all inﬂuenza
viruses, 34 inﬂuenza B, 530 inﬂuenza A(H1N1)pdm09, 622
inﬂuenza A(H3N2), one A(H1N1)pdm09/A(H3N2) co-infection and
22 inﬂuenza A not subtyped. Due to the small number of inﬂuenza
B cases, we restricted the analysis to inﬂuenza A(H1N1)pdm09 and
A(H3N2). After excluding patients with symptom onset outside the
deﬁned study period, we  included in the A(H1N1)pdm09 analysis
531 cases and 1712 controls and in the A(H3N2) analysis 623 cases
and 1920 controls (the case of co-infection was  included in both
analyses) (Fig. 1). The maximum weekly number of cases recruited
occurred in week 2, 2014 for A(H3N2) and in week 4, 2014 for
A(H1N1)pdm09 (Fig. 2).
Among the 3020 included individuals with information on vac-
cination status, 327 (10.8%) were vaccinated. The proportion of
vaccinated varied by study site from 7.6% in Romania (11 vacci-
nated) to 18.4% in Portugal (23 vaccinated).
Two  hundred eighty three (86.5%) of the vaccinated individ-
uals had information on the vaccine brand received; eight different
brands were used. By vaccine type, 63% had received inactivated
split vaccine, 19% inactivated subunit vaccine and 17% adjuvanted
vaccine.
The proportion vaccinated with the 2013–2014 inﬂuenza vac-
cine was  11.8% among controls, 6.5% among A(H1N1)pdm09 cases
and 11.7% among A(H3N2) cases (Table 2).
The median age was  lower in controls (24 years) compared
to A(H3N2) cases (33 years) and A(H1N1)pdm09 cases (35 years)
(Table 2). The proportion of patients belonging to the target group
for vaccination, or with at least one chronic condition or with at
least one hospitalisation in the previous 12 months was similar
between A(H3N2), A(H1N1)pdm09 cases and controls. Eighty-six
percent of controls were swabbed within three days of symptom
onset compared to 91.7%, and 90.5% of inﬂuenza A(H1N1)pdm09
and A(H3N2) cases, respectively.
After excluding patients with missing information on
2013–2014 seasonal vaccination status or date, onset date,
age, sex or presence of chronic condition, we included 2113 for
the complete case analysis of VE against inﬂuenza A(H1N1)pdm09
and 2369 for the analysis against A(H3N2).
The Q test and I2 index testing for heterogeneity of adjusted
VE between study sites suggested no statistical heterogeneity for
inﬂuenza A(H1N1)pdm09 (p = 0.695, I2 = 0%) and therefore we used
a one-stage model to estimate VE against A(H1N1)pdm09.
The overall VE against inﬂuenza A(H1N1)pdm2009 adjusted for
onset week, chronic conditions, age and sex, was 47.5% (95% CI:
16.4–67.0) (Table 3).
The adjusted VE was 64.4% (95% CI: −85.8–93.2) among the 0–14
years old, 38.8% (95% CI: −14.2–67.2) among the 15–59 years old.
The crude VE was 51.8% (95% CI: −05–76.9) among the 60 years and
more. Due to the small sample size in this group, adjustment was
not possible.
By vaccine type, the point estimate adjusted VE against
A(H1N1)pdm09 were higher for adjuvanted vaccines (72.6%;
95% CI −22.4–93.9) than for inactivated subunit (36.8%; 95% CI
−83.3–78.2)) or split virion (44.0%; 95% CI 5.0–65.0)) (Table 3).
In the sensitivity analyses, the overall adjusted VE against
A(H1N1)pdm09 was  46.7% (95% CI: 12.4–67.6) when restricting
to patients swabbed less than four days after onset of symp-
toms, 51.5% (95%CI: 14.2–72.6) when restricting to the target
group for vaccination, and 47% (95% CI 15.5–66.7) when exclud-
ing patients vaccinated less than 15 days before symptom onset
(Table 3).
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Table 1
Study details; Inﬂuenza vaccine effectiveness multicentre case-control study, study sites in six European Union countries, week 47/2013–week 19/2014.
Study site Week of start
of inﬂuenza
seasona
Week of peak
of inﬂuenza
seasona
Number of
practitioners recruiting
at least one ILI patientb
Number of ILI patientsb
included in study
Inclusion
period for the
ﬁnal analysis
(ISO weeks)c
Number of included ILI
patients positive to
inﬂuenza and with
known vaccination
statusd
Number of included ILI
patients negative for
any inﬂuenza and with
known vaccination
statusd
Germany Week 8/2014 Week 10/2014 99 1291 Week
47/2013–week
19/2014
178 18 992 98
Hungary  Week 6/2014 Week 8/2014 47 341 Week
3/2014–week
14/2014
83 6 258 40
Ireland  Week 6/2014 Week 9/2014 21 173 Week
51/2013–week
17/2014
103 8 70 14
Portugal  Week 1/2014 Week 4/2014 24 125 Week
50/2013–week
8/2014
77 9 48 14
Romania  Week 1/2014 Week 11/2014 58 147 Week
1/2014–week
15/2014
75 3 72 8
Spain  Week 1/2014 Week 4/2014 186 1119 Week
49/2013–week
15/2014
680 66 439 48
Total  435 3196 1196 110 1879 222
ILI: Inﬂuenza-like illness. ISO: International Organization for Standardization.
a According to the thresholds used to deﬁne the start of the inﬂuenza season in each of the countries.
b ILI patients meeting the European Commission case deﬁnition, swabbed less than eight days after onset of symptoms within the study period.
c From 15 days after the start of the vaccination campaign to week 19, 2014. We  excluded controls with onset of symptoms in the weeks before the week of the ﬁrst inﬂuenza case and after the week of the last inﬂuenza case
after  which there were two or more consecutive weeks of no cases in the study site.
d ILI patients included in the study, after excluding those with missing information on vaccination status or date of vaccination.
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(N=57 7)
Number of records received for pooled analysis: 
4292
Excluding records : 
• Persons with contraindicaons against vaccinaon (N=0)
• Persons administered anvirals prior to swabbing (N=0)
• Per sons with missing lab re sults (N =6)
• Per sons with missing onset dat e (N=142)
• With date of onset <15 days ae r begin of  vaccina on campa ign (N =1)
• Not  meen g th e EU ILI  case deﬁnion  (N =632)
• With inte rval between onset of  symptoms and swabbi ng >7 days (N=71)
Droppi ng records  wit h missi ng da ta for  complete case  ana lys is: 
Influenza A(H3N2) analysis  Influenza A(H1 N1) pdm09  
analysis  
• Excluding paents pre senng before  ISO week of ﬁrst t ype/subt ype-speciﬁ c inﬂuenza  cas e and 
aer ISO w eek of last type/subtype-speciﬁc inﬂuenza case aer which t here  are tw o consecuve 
weeks of n o cases (weeks  of sy mptom onset, by country) :
(N=55 6)
(N=32 1)
a In clud es 1A(H1N1)pd m09 A(H3N2) co-in feco n 
(N=64 2) (N=57 7) 
Influenza A(H3N2) analysis  
(N=11 3) 
 (N=60)  
Influenza A(H1 N1) pdm09 
analysis  
(N= 86) 
(N= 44) 
• Per sons with missing informaon on  age, s ex  or chronic dis eas e  
• Persons  with m iss ing 2013-20 14  inﬂuenza  vaccin aon stat us or date 
2243 
Cases: 531a
Cont rols  17 12 
2543
Cases: 623a
Cont rols  19 20 
Influenza A(H1 N1) pdm09 
complete case analysi s
2113 
Cases: 521a
Cont rols  15 92 
Influenza A(H3 N2) 
complete case analysi s
2370 
Cases: 613a
Cont rols  17 57 
• Dropping inﬂuenz a positive records of diﬀerent type/ subtype :
VE mu
a
c
a
sFig. 1. Flowchart of data exclusion for pooled analysis, I-MO
For A(H3N2), the I2 was 51.5% (p = 0.067), and therefore, we used
 two-stage model for the pooled VE analysis against A(H3N2). The
rude and adjusted VE varied by study site (Table 4). The overall
djusted VE was 30.2% (95% CI: −33.9–63.6). The adjusted two-
tage pooled VE against A(H3N2) was not calculated by age grouplti-centre case-control study, inﬂuenza season 2013–2014.
or vaccine group as adjustment was  not possible due to sparse data
by country.Eighty-two of the 531 A(H1N1)pdm09 viruses (15:4%) were
sequenced (Germany 5, Ireland 9, Portugal 12, Romania 3 and Spain
53). All clustered into the group 6, characterised by D97N and
2818 M. Valenciano et al. / Vaccine 33 (2015) 2813–2822
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185T substitutions, subgroup B, carrying additional substitutions:
163Q, K283E and A256T. The mutations K209T and R223Q were
resent in all the 82 viruses and may  be explained by egg adap-
ation. Other mutations present in all viruses were P83S, S203T. In
ddition, the mutation I321V was present in 54 of the 73 sequences
hat included this portion of the haemaglutinine gene (9 sequences
able 2
etails for inﬂuenza, A(H3N2) (n = 623)a, A(H1N1)pdm09 (n = 531)a cases and controlsa (n
nalysis, multicentre case control study in six European Union study sites, week 50 (2013
Variables 
Median age (Interquartile range), years 
Age  groups (years)
0–4
5–14  
15–64  
≥60  
Sex
Female 
Days  between onset of symptoms and swabbing
0 
1  
2  
3  
4–7  
Seasonal vaccination, 2013–2014c
2013–2014 inﬂuenza vaccine type
Inactivated subunit 
Inactivated split virion 
Adjuvanted 
At  least one chronic condition 
At  least one hospitalisation in the previous 12 months for chronic conditions 
Belongs to target group for vaccination 
Study  sites
Germany 
Hungary 
Ireland 
Portugal 
Romania 
Spain  
a One inﬂuenza cases positive for both inﬂuenza A(H1N1)pdm09 and A(H3N2) was inc
b Controls from “any inﬂuenza” analysis used.
c Vaccination more than 14 days before onset of inﬂuenza like illness symptoms.LI cases included in the study by week of symptom onset, pooled I-MOVE dataset,
from Ireland did not cover it). A total of 54/73 viruses harbored in
addition the mutation I321V. All seven viruses analysed by HI assay
were antigenically similar to the vaccine virus, A/California/7/2009
(less than 2-fold reduction in HI titre).
Of the 623 A(H3N2) viruses from patients included in the
analysis 102 (16.4%) were genetically characterised (Germany 21,
 = 1986) included in the 2013–2014 season trivalent inﬂuenza vaccine effectiveness
)–week 17 (2014), inﬂuenza season 2013–2014.
Number of
test-negative
controls b/total
n(%)
Number of
inﬂuenza
A(H1N1)pdm09b/total
n(%)
Number of inﬂuenza
A(H3N2) casesb./total
n(%)
24.0 (4–45) 35.0 (18–47) 33.0 (12–48)
498/1983 (25.1) 35/531 (6.6) 70/623 (11.2)
317/1983 (16.0) 80/531 (15.1) 109/623 (17.5)
969/1983 (48.9) 374/531 (70.4) 366/623 (58.7)
199/1983 (10.4) 42/531 (7.9) 78/623 (12.5)
1031/1976 (52.2) 262/531 (49.3) 308/621 (49.6)
142/1986 (7.2) 18/531 (3.4) 32/623 (5.1)
723/1986 (36.4) 214/531 (40.3) 230/623 (36.9)
522/1986 (26.3) 168/531 (31.6) 193/623 (31.0)
318/1986 (16.0) 87/531 (16.4) 109/623 (17.5)
281/1986 (14.0) 44/531 (8.4) 59/623 (9.0)
222/1879 (11.8) 34/523 (6.5) 72/617 (11.7)
37/1843 (1.9) 5/521 (0.9) 13/611 (2.1)
105/1843 (5.3) 25/521 (4.7) 49/611 (7.9)
43/1843 (2.2) 2/521 (0.4) 4/611 (0.6)
389/1920 (20.3) 102/529 (19.3) 128/616 (20.8)
32/1964 (1.6) 6/529 (1.1) 10/620 (1.6)
499/1953(25.6) 131/531 (24.7) 163/619 (26.3)
1099/1986 (55.3) 57/531 (10.7) 117/623 (18.8)
258/1986 (13.0) 41/531 (7.7) 26/623 (4.2)
70/1986 (3.5) 41/531 (7.1) 54/623(8.7)
48/1986 (2.4) 49/531 (9.2) 28/623 (4.5)
72/1986 (3.6) 19/531 (3.6) 52/623 (8.3)
439/1986 (22.1) 324/531 (61.0) 346/623(55.5)
luded in the analysis.
M.  Valenciano et al. / Vaccine 33 (2015) 2813–2822 2819
Table  3
Pooled one-stage model crude and adjusted seasonal vaccine effectiveness against laboratory conﬁrmed inﬂuenza A(H1N1)pdm09 overall, by age group and by vaccine type.
Multicentre case-control study in six European Union study sites, week 50 (2013)–week 17 (2014), inﬂuenza season 2013–2014.
Analysis scenarios, population included A(H1N1)pdm09 VE (%) (95%CI)
Primary analysis All age groupsa N (cases/vaccinated;
controls/vaccinated)
2113 (521/34; 1592/203)
Crude 52.2 (30.3–67.3)
Crude (study site as ﬁxed effect) 57.4 (36.3–71.5)
Adjusted for sex 57.6 (36.5–68.7)
Adjusted for chronic condition 55.6 (34.9–67.5)
Adjusted for age (cubic spline) 49.1 (20.5– 67.5)
Adjusted for onset week, age (cubic
spline)
48.5 (18.7–67.3)
Adjusted for onset week, chronic
condition
54.5 (30.2–70.4)
Adjusted for study site, onset week, age
(cubic spline), chronic conditions, sex
47.5 (16.4–67.0)
0–14  years old N (cases/vaccinated;
controls/vaccinated)
698 (110/2; 588/46)
Crude 78.2 (8.8–94.8)
Crude (study site included as ﬁxed
effect)
75.6 (−17.0–94.9)
Adjusted for study site, onset month,
age (cubic spline),chronic conditiona
64.4 (−85.8–93.2)
15–59  years oldb N (cases/vaccinated;
controls/vaccinated)
1189 (369/17; 820/61)
Crude 39.9 (−4.4–65.4)
Crude (study site included as ﬁxed
effect)
37.1 (–12.7–64.9)
Adjusted for study site, onset week, age
(cubic spline), chronic condition, sexc
38.8 (−14.2–67.2)
60  years old and
aboved
N (cases/vaccinated;
controls/vaccinated)
226 (42/15; 184/96)
Crude 49.1 (−2.0–74.9)
Crude (study site included as ﬁxed
effect)
51.8 (−0.5–76.9)
Adjusted Too few cases
Analysis by vaccine
type
N (cases/vaccinated subunit/vaccinated
split virion/vaccinated adjuvanted;
controls/vaccinated
subunit/vaccinated split
virion/vaccinated adjuvanted)
2113 (521/5/25/2/;
1592/32/99/43)
Crudee subunit 51.4 (−34.1–82.4)
Crudee split virion 53.7 (25.3–71.3)
Crudee adjuvanted 79.2 (10.7–95.1)
Adjustedf subunit 36.8 (−83.3–78.2)
Adjustedf split virion 44.0 (5.0–65.0)
Adjustedf adjuvanted 72.6 (−22.4–93.9)
Sensitivity analysis Restricted to target
group for vaccinationg
N (cases/vaccinated;
controls/vaccinated)
528 (130/26; 398/144)
Crude 55.9 (29.0–72.6)
Crude (study site included as ﬁxed
effect)
60.6 (34.9–76.2)
Adjusted for study site, onset week, age
(cubic spline), chronic condition, sex
51.5 (14.2–72.6)
Restricted to those
with delay onset and
swabbing < 4 days
N (cases/vaccinated;
controls/vaccinated)
1846 (477/30; 1369/163)
Crude 50.3 (25.6–66.9)
Crude (study site included as ﬁxed
effect)
58.0 (35.4–72.7)
Adjusted for study site, onset week, age
(cubic spline), chronic condition, sex
46.7 (12.4–67.6)
Individuals
vaccinated < 15 days
excluded
N  (cases/vaccinated;
controls/vaccinated)
2108 (519/34; 1589/203)
Crude 52.1 (30.2–67.2)
Crude (study site included as ﬁxed
effect)
57.3 (36.1–71.4)
Adjusted for study site, onset week, age
(cubic spline), chronic condition, sex
47.0 (15.5–66.7)
a Portugal excluded (four cases unvaccinated).
b Weeks of inclusion: week 50 (2013)–week 17(2014).
c Week 16 excluded (one record dropped).
d Weeks of inclusion: week 52(2013)–week 13 (2014).
e Study site included as ﬁxed effect.
f Adjusted for study site, onset week, age (cubic spline), chronic condition, sex.
g Weeks of inclusion: week 50 (2013) week 13 (2014).
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Table 4
One-stage and two-stage pooled crude and adjusted seasonal vaccine effectiveness against laboratory conﬁrmed inﬂuenza A(H3N2) overall and by age group. Multicentre
case  control study in six European Union study sites, week 47 (2013)–week 19 (2014), inﬂuenza season 2013–2014.
Study site N (cases/vaccinated;
controls/vaccinated)
VE (%) 95% CI
All ages crude
estimates
Germany 1045 (107/15; 938/94) −46.4 (−163.0 18.5)
Hungary 223 (26/1; 197/33) 80.1 (−51.9–97.4)
Ireland 122 (54/5; 68/14) 60.6 (−17.3–86.8)
Portugal 75 (28/6; 47/14) 35.7 (−92.7–78.6)
Romania 124 (52/1; 72/8) 84.3 (−29.5–98.1)
Spain 781 (346; 44/435/48) −17.5 (−81.6–24.0)
2-stage crude pooled estimate
Heterogeneity chi-squared = 10.95 (df = 5), p = 0.052 I-squared = 54.4%
2370 (613,72/1757,211) 24.6 (−33.4–57.4)
All  ages adjusted
estimates
Germany
Adjusted for onset week (cubic spline), chronic condition, age (cubic
spline), sex
1045 −36.4 (−160.0–28.5)
Hungary
Adjusted for age group (two categories 18–59, 60+)
223 91.6 (26.4–99.0)
Ireland
Adjusted for onset month, chronic condition, age group (three categories:
0–14, 15–59, 60+)
122 60.7 (−41.4–89.1)
Portugal
Adjusted for onset month, chronic condition, age group (two categories:
0–59, 60+)
75 23.0 (−209–80.9)
Romania
Adjusted for onset month, chronic condition, age group (three categories:
0–14, 15–59, 60+)
124 82.7 (−66.0–98.2)
Spain
Adjusted for onset week (cubic spline), chronic condition, age (cubic
spline), sex
781 −12.2 (−95.7–35.7)
2-stage adjusted pooled estimate
Heterogeneity chi-squared = 10.43 (d.f. = 5), p = 0.064 I-squared = 52%
2370 (613,72/1757,211) 30.2 (−33.9–63.6)
15–59  years crude
estimates
Germany 347 (37/3; 310/26) 3.6 (−235.4–73.3)
Hungary 181 (19/0; 162/11) NA NA
Ireland 82 (34/2; 48/6) 56.3 (−131.3–91.7)
Portugal 49 (15/2; 34/5) 10.8 (−421.5–84.7)
Romania 69 (30/1; 39/3) 58.6 (−319.2–95.9)
Spain 497 (228/14; 269/14) −19.2 (−155.5–44.4)
2-stage crude pooled estimate (Hungary excluded)
Heterogeneity chi-squared = 1.67, (df = 4) p = 0.796 I-squared = 0.0 = %
1044 (76/22; 968/322) 6.6 (−62.9–46.5)
60  years and over
crude estimatesa
Germany 64 (7/2; 57/24) 45.0 (−207.8–90.2)
Hungary 42 (7/1; 35/22) 90.2 (8.8–98.9)
Ireland 17 (4/2; 13/7) NA NA
Portugal 23 (10/4; 13/9) 70.4 (−66.9–94.7)
Romania 16 (5/0; 11/5) NA NA
Spain  102 (45/29; 57/28) −87.7 (−318.4–15.8)
uared
ce in
H
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v
(
v
t
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h
T
N
c2-stage crude pooled estimate
Heterogeneity chi-squared = 8.89 (df 3) p = 0.031 I-sq
a Weeks of inclusion 50 (2013)–14 (2014); VE: vaccine effectiveness; CI: conﬁden
ungary 1, Ireland 8, Portugal 4, Romania 4 and Spain 64) (Table 5).
ll clustered into the group 3C corresponding to the recommended
accine virus for the 2013–14 seasons A/Texas/50/2012.
We identiﬁed 12 amino acid position changes. Three of these
V186G, F219S and N226I) were present in the 102 analysed
iruses and could be explained by egg adaptation. Four muta-
ions (N128T/A, R142G, N145S and P198S) were already present in
(H3N2) viruses circulating in 2012–2013. Sixty three viruses (62%)
arbored mutations detected for the ﬁrst time in the 2013–2014
able 5
umber of strains with amino acid changes in the Haemagglutinin genes A(H3N2) relative
ases-control study inﬂuenza, inﬂuenza season 2013–2014.
Study site Subgroup 3 C.2 Subgroup 3 C.3
N128T N128A, R142G L
Germany 5 10 
Hungary 1
Ireland 1 
Portugal 2 1 
Romania 1 
Spain 6 12 
Total 14 25 1 = 66.3%
231 (69/36; 162/83) 47.4 (−97.5–86.0)
tervals; NA: not applicable; df: degrees of freedom.
season. All 63 presented the L157S mutation located in the B anti-
genic site close to the receptor binding site; 51 of them had a second
mutation located in the A antigenic (N122D) and six of these three
additional mutations located in the E antigenic site (E62K, K83R
and R261Q) were in six of these viruses (Table 5).
Among the 12 A(H3N2) viruses analysed by HI, nine showed
an eightfold or higher reduction in HI antibody titers when using
post-infection ferret antiserum raised against the egg-propagated
A/Texas/50/2012 vaccine virus. The 12 viruses presented ≤4-fold
 to vaccine reference strain by genetic subgroup and study site. I-MOVE multicentre
157S L157S; N122D L157S; N122D; E62K; K83R; R261Q
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eduction when using ferret antisera raised against other viruses
imilar to A/Texas/50/2012 propagated in cells.
. Discussion
The results of the I-MOVE multicentre case control suggest a
oderate 2013–2014 inﬂuenza VE against A(H1N1)pdm09 and a
ow VE against A(H3N2).
All the overall adjusted estimates for A(H1N1)pdm09 includ-
ng those calculated in the sensitivity analysis ranged between
6.7% and 51.5%. They were similar to our estimates in 2012–2013
50.4%) and 2011–2012 (56.1%) [5,6]. The highest point VE was
mong children 0–14 years and the lowest among those aged 60
ears and over. However, the low proportion of children vaccinated
8.2% vaccinated among controls) and the small sample size among
atients aged 60 years and over resulted in imprecise estimates.
he laboratory results indicate that the strains isolated from study
articipants were similar to that included in the vaccine.
Among those vaccinated, the completeness of vaccination status
as good (87%). The point estimate VE was higher for adjuvanted
accines but the small sample size resulted in imprecise estimates.
ith the large number of inﬂuenza vaccines used in Europe and
he low vaccination coverage, a much larger sample size is needed
o provide VE by product as requested by EMA  [2].
The VE against A(H3N2) was similar to the estimates from the
011–2012 I-MOVE MCC  (24.8%) [4]. In February 2014 Spain and
avarra region, sites included in the MCCS reported early estimates
f 28% and 13% against A(H3N2) respectively [10,11]. In Navarra,
nd Ireland A(H3N2) outbreaks in highly vaccinated nursing homes
ccurred in the 2013–2014 winter suggesting poor performance of
he vaccine [10,12]. The low VE observed could be explained by the
mino acid mutations located in the B antigenic site, close to the
eceptor binding site. Changes in close amino acid positions in the B
ntigenic site (155, 156, 158 and 159) have determined major anti-
enic changes during the inﬂuenza virus evolution [13]. However,
he results indicate that the viruses from patients included in our
tudy were antigenically similar to the 2013–2014 vaccine virus.
For the ﬁrst time since 2008–2009, the estimates for A(H3N2)
ere heterogeneous among study sites. To account for this het-
rogeneity, we used a two-stage model to provide pooled adjusted
stimates. Two-stage models give more weight to small study sites
han a one-stage model, if there is heterogeneity [14]. In a two-
tage model, the sample size required by study site is higher as we
ool study site adjusted VE. Because of sparse data, we  could only
rovide overall adjusted VE.
Several factors can explain the heterogeneity among study
ites. First, a different application of the study protocol may
esult in heterogeneity. However, all sites had already partici-
ated in previous I-MOVE MCCS and there were no changes in
he study procedures at study site level compared to previous
easons. Moreover, if there were differences in the application of
he protocol we would also expect heterogeneity between study
ites for the A(H1N1)pdm09 VE estimates. Second, heterogene-
ty may  be due to difference in the viruses circulating in the
articipating study sites or to different vaccines being used. The
imited number of viruses characterised by study site and the small
umber of individuals vaccinated with each of the vaccines did
ot allow the veriﬁcation of this hypothesis. Third, we  cannot
xclude the presence of information or selection bias. However,
f bias was present, we would also expect high heterogeneity
or A(H1N1)pdm09 VE estimates. Fourth, the low vaccine cov-
rage in controls and the small sample sizes for stratiﬁcation
esulted in a very high variability of the estimates. In any case,
f presence of statistical heterogeneity is identiﬁed in the future,
arger sample sizes by study site should be achieved to provide 33 (2015) 2813–2822 2821
two-stage pooled VE for all subgroup analysis and for better inter-
pretation of the results.
VE against A(H1N1)pdm09 was  moderate and in the range
of what we have observed since the pandemic. The VE against
A(H3N2) was lower with heterogeneous estimates among study
sites. As in 2012–2013 the high completeness of the informa-
tion on the vaccine product allowed having estimates by vaccine
type but the low vaccination coverage impeded having estimates
by product. The I-MOVE MCCS is a strong network of scientists
who through robust methods can provide information needed to
guide inﬂuenza vaccination programmes in the EU/EEA. However,
in order to provide precise EU estimates by age group and vaccine-
product and to account for potential heterogeneity, a larger sample
size and a higher number of study sites are needed. In addition
to better integrate the laboratory results in the interpretation of
inﬂuenza VE estimates, the number and representativeness of virus
strains characterised should be increased.
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